Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests whether a 'Research Navigator' boosts cancer trial enrollment

NCT ID NCT06618274

Knowledge-focused Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether adding an oncology research navigator (ORN) to standard cancer navigation helps patients with cancer. About 686 adults with new cancer appointments will take part. Some will get the usual navigation, while others also get an ORN who helps them find supportive services and clinical trials. The goal is to see if this improves quality of life and increases participation in studies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oncology research navigator (a dedicated staff member who helps patients access supportive services and clinical trials)
What this could lead to
If successful, this could show that having a research navigator helps more cancer patients enroll in clinical trials and use supportive care services, potentially improving their quality of life.
What could go wrong
This is a health services study, not a drug trial, so it won't directly treat cancer. The results may depend on the specific hospital setting and might not apply everywhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 686 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Jul 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: In order to participate in this study a subject must meet all of the eligibility criteria outlined below. * Informed consent obtained to participate in the study and HIPAA authorization for release of personal health information. * Subject is willing and able to comply with study activities based on the judgement of the investigator. * Age ≥ 18 years at the time of consent. * Subject has a new patient appointment for cancer care at a UNC Medical Center and a confirmed cancer diagnosis. Exclusion Criteria: * Lack of internet access. * Inability to understand the English language. * Psychological or other disability resulting in the inability to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer cancer digestive system cancer hematopoietic and lymphoid cell neoplasm malignant urinary system neoplasm neoplasm thoracic cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Malignant tumor

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UNC Lineberger Comprehensive Cancer Center

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.